The FDA on December 16, 2020 approved MARGENZA® in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA® is a product of MacroGenics, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
